Inpatient Fundamentals

Context: Inpatients have volatile medications, nutritional

intake, and physiologic stress that can all alter


glucose metabolism.

Current: Inpatient hyperglycemia correlates with inpatient

mortality. Goal inpatient glucose is 140 - 180.

Cutting Edge: If ≥ 2 readings are ≥ 180 in 24 hours, then

diabetes medications need to be adjusted.



Oral Diabetic Medications

Context: All oral antihyperglycemic medications have traditionally been held during inpatient admission.

Current: Basal-bolus insulin is still often the optimal initial strategy during hospitalization.² Sliding scale


insulin monotherapy is unlikely to be effective.³ It is probably safe to introduce non-insulin therapies

prior to discharge after stabilization.

Cutting Edge: Sulfonylureas and SGLT-2 inhibitors are best held throughout. Metformin, pioglitazone, and

possibly DPP-4 inhibitors can sometimes be safetly continued.

Steroid-Induced Hyperglycemia



Context: Steroids lead to predictable peaks and troughs in blood glucose.

Current: Matching insulin to steroids may help. Hydrocortisone may respond well to regular or NPH insulin, while prednisone and methylprednisolone track well with NPH or detemir.⁵

Cutting edge: A1C on admission can help guide discharge therapy. Specifically, A1C 7-10 warrants outpatient medication adjustment and A1C >10 warrants addition of outpatient insulin.

Classes of Medications

Context: Antihyperglycemic medications have traditionally been indicated only for diabetes.

Current: Antihyperglycemics are rapidly accumulating indications for cardiovascular and kidney disease.⁶

Specifically:

- SGLT-2 inhibitors for CAD, HF, & stroke/TIA - GLP1-RAs for CAD, stroke/TIA, & CKD Reduce ASCVD and Kidney Risks Based on Comorbidities

CAD HFrEF HFPEF CKD Stroke/TIA

LA GLP1-RA SGLT2i SGLT2i LA GLP1-RA

SGLT2i LA GLP1-RA

Pio

Cutting Edge: Hospitalists are increasingly

responsible for starting these medications on or before discharge and embracing their role in chronic

disease management.

References:

- Umpierrez, et al. Hyperglycemia: An Independent Marker of In-Hospital Mortality in Patients with Undiagnosed Diabetes, J Clin Endocrinol Metab. 2002;87(3):978
- 2. Korytkowski, et al. Management of Hyperglycemia in Hospitalized Adult Patients in Non-Critical Care Settings: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2022;107(8):2101
- 3. Ambrus, et al. Things We Do For No Reason: Sliding-Scale Insulin as Monotherapy for Glycemic Control in Hospitalized Patients. J Hosp Med. 2019;14(2):114
- 4. Cohen, et al. Things we do for no reason: Routinely holding metformin in the hospital. J Hosp Med. 2022;17(3):207
- 5. Aberer, et al. A Practical Guide for the Management of Steroid Induced Hyperglycaemia in the Hospital. J Clin Med. 2021;10(10):2154
- 6. Handelsman, et al. Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. J Diabetes Complications. 2022;36(2):108